Размер шрифта
Цветовая схема
Изображения
Форма
Межсимвольный интервал
Межстрочный интервал
стандартные настройки
обычная версия сайта
закрыть
  • Вход
  • Регистрация
  • Помощь
Выбрать БД
Простой поискРасширенный поискИстория поисков
Главная / Результаты поиска

Development and validation of valganciclovir and its active metabolite ganciclovir determination in human plasma by HPLC-UV method

Комаров Т. Н., Шохин И. Е., Мискив О. А., Богданова Д. С., Алешина А. В., Медведев Ю. В., Багаева Н. С.
Разработка и регистрация лекарственных средств
Т. 9, Вып. 2, С. 133-139
Опубликовано: 2020
Тип ресурса: Статья

DOI:10.33380/2305-2066-2020-9-2-133-139

Аннотация:
Introduction. Viral infections are a serious problem that occurs during the use of immunosuppressants in preparation for organ transplantation and in the postoperative period. Cytomegalovirus (CMV) infection is one of the main causes of diseases in people with weakened immune systems. It has a direct impact on one’s body and makes it more likely to reject a transplanted organ. Antiviral drugs are used to treat and prevent this infectious disease. Valganciclovir is a prodrug whose active metabolite is ganciclovir. Valganciclovir is the drug of choice in the treatment of CMV infections. Currently, there are no researches on the matter of simultaneous determination of both valganciclovir and ganciclovir in human blood plasma by means of high-performance liquid chromatography (HPLC) with ultraviolet detection. This research delivers a thorough description of development and validation of a particular method for simultaneous determination of valganciclovir and ganciclovir in the plasma afte
Ключевые слова:
Bioequivalence; Ganciclovir; HPLC-UV; Plasma; Quantitative determination; Valganciclovir; Validation
Язык текста: Русский
ISSN: 2305-2066
Комаров Т. Н.
Шохин И. Е. Игорь Евгеньевич 1985-
Мискив О. А.
Богданова Д. С.
Алешина А. В.
Медведев Ю. В. Юрий Владимирович 1983-
Багаева Н. С.
Komarov T. N.
Shokhin I. E. Igor` Evgenyevich 1985-
Miskiv O. A.
Bogdanova D. S.
Aleshina A. V.
Medvedev Yu. V. Yurij Vladimirovich 1983-
Bagaeva N. S.
Development and validation of valganciclovir and its active metabolite ganciclovir determination in human plasma by HPLC-UV method
Текст визуальный непосредственный
Разработка и регистрация лекарственных средств
Фармконтракт
Т. 9, Вып. 2 С. 133-139
2020
Статья
Bioequivalence Ganciclovir HPLC-UV Plasma Quantitative determination Valganciclovir Validation
Introduction. Viral infections are a serious problem that occurs during the use of immunosuppressants in preparation for organ transplantation and in the postoperative period. Cytomegalovirus (CMV) infection is one of the main causes of diseases in people with weakened immune systems. It has a direct impact on one’s body and makes it more likely to reject a transplanted organ. Antiviral drugs are used to treat and prevent this infectious disease. Valganciclovir is a prodrug whose active metabolite is ganciclovir. Valganciclovir is the drug of choice in the treatment of CMV infections. Currently, there are no researches on the matter of simultaneous determination of both valganciclovir and ganciclovir in human blood plasma by means of high-performance liquid chromatography (HPLC) with ultraviolet detection. This research delivers a thorough description of development and validation of a particular method for simultaneous determination of valganciclovir and ganciclovir in the plasma afte